At-Home Diagnostics for Precision Hormone Tracking
Unravel Health is building a palm-sized lab to let women measure key hormones at home using saliva samples in just minutes.

For decades, understanding personal hormonal health has required clinical appointments, invasive blood draws, and lengthy waiting periods for laboratory results. While saliva carries the essential hormones that regulate human biological systems, these chemical markers exist in microscopic quantities that traditionally required heavy laboratory machinery to detect accurately. Frustrated by how little standard blood tests revealed about complex ongoing symptoms, data and product leader Veronika Bridgman sought a far more continuous way to track daily biological shifts. In 2024, she co-founded Unravel Health alongside chief commercial officer Liza Levy and chief medical officer Dr Alexandra Oti to address this gap in diagnostic access.
The foundation of Unravel Health rests on an academic breakthrough that took a decade to refine. The underlying sensor technology was developed over ten years of dedicated research at the University of Glasgow and is protected by three granted patents. This scientific foundation allows the team to isolate and quantify trace molecules in fluid samples without requiring large diagnostic instruments. By bringing university research into a commercial venture, the founders aim to remove the technical friction that has long separated consumers from their personal biological data.
The company's primary innovation is the Micro Lab, a compact hardware platform designed to fit comfortably in the palm of a hand. Instead of requiring painful blood draws, the system analyses a simple saliva sample to measure multiple target hormones simultaneously in just a few minutes. By capturing these dynamic signals at home, the platform aims to build a rich, structured data layer for hormone-linked health across various life stages. The rapid feedback loop helps transform static medical measurements into an actionable, ongoing record of physical health.
Hormonal wellness rarely depends on a single chemical isolated from the rest of the body. The Micro Lab is engineered to evaluate interconnected hormonal markers together, beginning with oestradiol, which functions as the principal form of oestrogen in female biology. By tracking how these key levels fluctuate over days and weeks, the device reveals underlying patterns that single-point blood tests usually miss. Liza Levy and the team aim to turn this deep biological tracking into an effortless daily habit that fits smoothly into existing household routines.
To move the technology toward commercial production, Unravel Health secured 2.96 million euros in pre-seed funding. The team is deploying this capital toward external equivalency studies, which compare the accuracy of the Micro Lab directly against established clinical laboratory standard methods. Alongside validation trials, the startup is expanding its platform to measure additional biological markers and beginning formal regulatory approval processes. Dr Alexandra Oti guides the clinical strategy to ensure that all data collected meets the stringent requirements of healthcare regulators.
The company plans to roll out its first early-access Micro Lab devices in 2027 through strategic channels, including pharmacy networks, digital health platforms, and clinical providers. Unravel Health will also showcase its progress at Slush 2026 as it prepares for wider market entry and regulatory milestones. By shifting complex fluid diagnostics out of centralised laboratories and into daily life, the team is working to make personal health insights accessible, precise, and practical.
Find out more at unravel.health
The Future FrontBe on the cover.Twice a month we put the people shaping what's next on our cover.Apply for the cover





